Projects funded by the NCN
Synthetic epidermal growth factor receptor inhibitor conjugated with nobel metal nanoparticles as a potential drug for targeted therapy against pancreatic cancer
2021/41/N/NZ7/04480
Keywords:
EGFR inhibitor-Au nanopraticle coniugates EGFR inhibitor-Ag nanopraticle coniugates Targeted therapy Pancreatic cancer organoids Patient-derived organoids pancreatic cancer xenograft
Descriptors:
- NZ5_7: Human disease treatment
- NZ7_14: Pharmacy, pharmacotherapy, pharmacology
- ST5_10: Functional materials/nanomaterials, nanoparticles
Panel:
NZ7 - Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology
Host institution :
Gdański Uniwersytet Medyczny, Wydział Farmaceutyczny
woj. pomorskie
Principal investigator (from the host institution):
Number of co-investigators in the project: 3
Call: PRELUDIUM 20 - announced on 2021-03-15
Amount awarded: 209 993 PLN
Project start date (Y-m-d): 2022-02-04
Project end date (Y-m-d): 2025-02-03
Project duration:: 36 months (the same as in the proposal)
Project status: Pending project
Project description
Download the project description in a pdf file
Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.